Mark S Freedman

List of Publications by Citations

181 papers	14,680 citations	52 h-index	119 g-index
191 ext. papers	18,011 ext. citations	7.3 avg, IF	6.24 L-index

#	Paper	IF	Citations
181	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurology, The*, **2018**, 17, 162-173	24.1	2419
180	Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*, **2014**, 83, 278-86	6.5	1632
179	Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *New England Journal of Medicine*, **2011**, 365, 1293-303	59.2	662
178	Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. *Annals of Neurology*, **2009**, 66, 460-71	9.4	629
177	Quantifying axonal loss after optic neuritis with optical coherence tomography. *Annals of Neurology*, **2006**, 59, 963-9	9.4	466
176	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. *Lancet, The*, **2007**, 370, 389-97	40	417
175	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurology, The*, **2014**, 13, 247-56	24.1	363
174	Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. *Archives of Neurology*, **2005**, 62, 865-70		348
173	Vitamin D as an early predictor of multiple sclerosis activity and progression. *JAMA Neurology*, **2014**, 71, 306-14	17.2	312
172	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurology, The*, **2009**, 8, 987-97	24.1	279
171	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2016**, 387, 1075-1084	40	271
170	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. *Multiple Sclerosis Journal*, **2014**, 20, 705-16	5	237
169	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. *Lancet, The*, **2016**, 388, 576-85	40	234
168	Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. *Lancet Neurology, The*, **2011**, 10, 649-56	24.1	231
167	Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet Neurology, The*, **2014**, 13, 353-63	24.1	212
166	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurology, The*, **2014**, 13, 977-86	24.1	208
165	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. *Multiple Sclerosis Journal*, **2010**, 16, 503-10	5	185

164	Inclusion of brain volume loss in a revised measure of no evidence of disease activity (NEDA-4) in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 1297-305	5	169
163	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. *Lancet Neurology, The*, **2013**, 12, 756-67	24.1	163
162	Treatment optimization in MS: Canadian MS Working Group updated recommendations. *Canadian Journal of Neurological Sciences*, **2013**, 40, 307-23	1	159
161	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. *Lancet Neurology, The*, **2014**, 13, 257-67	24.1	156
160	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. *Lancet Neurology, The*, **2012**, 11, 33-41	24.1	153
159	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. *Lancet Neurology, The*, **2018**, 17, 405-415	24.1	150
158	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. *JAMA Neurology*, **2017**, 74, 459-469	17.2	147
157	Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. *Annals of Neurology*, **2008**, 63, 254-62	9.4	142
156	Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. *Multiple Sclerosis Journal*, **2012**, 18, 1278-89	5	112
155	Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes. *Annals of Neurology*, **1991**, 30, 794-800	9.4	112
154	Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. *New England Journal of Medicine*, **2017**, 376, 2122-2133	59.2	111
153	Chronic cerebrospinal venous insufficiency and multiple sclerosis. *Annals of Neurology*, **2010**, 67, 286-90	9.4	107
152	Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. *Annals of Neurology*, **2013**, 73, 341-54	9.4	105
151	Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 1198-208	5.5	105
150	Treatment optimization in multiple sclerosis. *Canadian Journal of Neurological Sciences*, **2004**, 31, 157-68	1	93
149	Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. *Neurology*, **2013**, 81, 552-8	6.5	90
148	Aggressive multiple sclerosis: proposed definition and treatment algorithm. *Nature Reviews Neurology*, **2015**, 11, 379-89	15	82
147	Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. *Neurology*, **2016**, 86, 920-30	6.5	80

146	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. *Neurology*, **2016**, 87, 978-87	6.5	78
145	Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. *Multiple Sclerosis and Related Disorders*, **2014**, 3, 696-704	4	76
144	Therapy of MS. *Clinical Neurology and Neurosurgery*, **2010**, 112, 365-85	2	74
143	Cytokine induction of heat shock protein expression in human oligodendrocytes: an interleukin-1-mediated mechanism. *Journal of Neuroimmunology*, **1994**, 50, 17-24	3.5	69
142	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. *JAMA Neurology*, **2016**, 73, 1089-98	17.2	67
141	Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. *Multiple Sclerosis Journal*, **2012**, 18, 1625-32	5	66
140	Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. *Multiple Sclerosis Journal*, **2013**, 19, 1310-9	5	60
139	Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. *Annals of Neurology*, **2010**, 68, 540-5	9.4	60
138	Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. *Neurotherapeutics*, **2013**, 10, 68-76	6.4	59
137	Reaction time: An alternative method for assessing the effects of multiple sclerosis on information processing speed. *Archives of Clinical Neuropsychology*, **2007**, 22, 655-64	2.7	59
136	Differential expression of heat shock proteins by human glial cells. *Journal of Neuroimmunology*, **1992**, 41, 231-8	3.5	59
135	Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. *Multiple Sclerosis and Related Disorders*, **2016**, 5, 97-104	4	59
134	Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. *Journal of Neurology*, **2008**, 255, 480-7	5.5	58
133	Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. *Therapeutic Advances in Chronic Disease*, **2016**, 7, 18-33	4.9	57
132	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 94-105	5	56
131	The prognostic significance of cerebrospinal fluid in multiple sclerosis. *Journal of the Neurological Sciences*, **2009**, 279, 21-5	3.2	55
130	Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. *Journal of Clinical & Cellular Immunology*, **2013**, 04,	2.7	55
129	Characterising aggressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1192-8	5.5	51

128	Sodium intake and multiple sclerosis activity and progression in BENEFIT. *Annals of Neurology*, **2017**, 82, 20-29	9.4	50
127	Mesenchymal stem cells as treatment for MS - progress to date. *Multiple Sclerosis Journal*, **2013**, 19, 515-9	3	50
126	Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. *Journal of Neuroimmunology*, **1998**, 87, 49-61	3.5	48
125	Vascular headache: a presenting symptom of multiple sclerosis. *Canadian Journal of Neurological Sciences*, **1989**, 16, 63-6	1	48
124	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. *Multiple Sclerosis Journal*, **2012**, 18, 1466-71	5	47
123	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 845-854	4.7	46
122	Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian contribution to the international validation project. *Journal of the Neurological Sciences*, **2016**, 362, 147-52	3.2	44
121	Selective effects of LSD and hyperthermia on the synthesis of synaptic proteins and glycoproteins. *Brain Research*, **1981**, 207, 129-45	3.7	44
120	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. *Multiple Sclerosis and Related Disorders*, **2014**, 3, 147-55	4	43
119	Using retinal architecture to help characterize multiple sclerosis patients. *Canadian Journal of Ophthalmology*, **2010**, 45, 520-6	1.4	43
118	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. *Trials*, **2019**, 20, 263	2.8	41
117	Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. *European Neurology*, **2008**, 60, 1-11	2.1	41
116	Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. *Archives of Neurology*, **2007**, 64, 1292-8		41
115	Human oligodendrocytes are susceptible to cytolysis by major histocompatibility complex class I-restricted lymphocytes. *Journal of Neuroimmunology*, **1990**, 27, 89-97	3.5	41
114	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. *Neurology*, **2015**, 85, 1694-701	6.5	39
113	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. *Annals of Clinical and Translational Neurology*, **2014**, 1, 605-17	5.3	39
112	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. *JAMA Neurology*, **2021**, 78, 558-567	17.2	39
111	COVID-19 in teriflunomide-treated patients with multiple sclerosis. *Journal of Neurology*, **2020**, 267, 2790-2796	3.3	37

110	Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. *Scientific Reports*, **2020**, 10, 10381	4.9	35
109	CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis. *Clinical Immunology*, **2008**, 128, 219-27	9	35
108	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. *CNS Drugs*, **2020**, 34, 185-196	6.7	32
107	Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 1076-83	4.7	32
106	Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. *Journal of Neurology*, **2013**, 260, 2472-80	5.5	31
105	Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. *Frontiers in Immunology*, **2018**, 9, 834	8.4	28
104	Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. *Archives of Neurology*, **2009**, 66, 1345-52		28
103	Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. *Journal of Clinical & Cellular Immunology*, **2013**, 4,	2.7	28
102	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurology, The*, **2020**, 19, 988-997	24.1	28
101	Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. *Multiple Sclerosis and Related Disorders*, **2016**, 10, 204-212	4	28
100	Production of soluble autocrine inhibitory factors by human glioma cell lines. *Journal of the Neurological Sciences*, **1992**, 110, 178-85	3.2	26
99	High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e598	9.1	26
98	Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. *Canadian Journal of Neurological Sciences*, **2018**, 45, 489-503	1	25
97	Correlation of specialized CD16(+) gammadelta T cells with disease course and severity in multiple sclerosis. *Journal of Neuroimmunology*, **2008**, 194, 147-52	3.5	25
96	Neuro-oncology dilemma: Tumour or tumefactive demyelinating lesion. *Multiple Sclerosis and Related Disorders*, **2015**, 4, 555-66	4	24
95	The Computerized Test of Information Processing (CTIP) offers an alternative to the PASAT for assessing cognitive processing speed in individuals with multiple sclerosis. *Cognitive and Behavioral Neurology*, **2010**, 23, 192-8	1.6	24
94	gamma delta T-cell-human glial cell interactions. I. In vitro induction of gammadelta T-cell expansion by human glial cells. *Journal of Neuroimmunology*, **1997**, 74, 135-42	3.5	24
93	Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. *Multiple Sclerosis Journal*, **2005**, 11, 227-31	5	24

92	Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 285-294	5.5	23
91	Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 420-431	5	22
90	Teriflunomide in relapsing multiple sclerosis: therapeutic utility. *Therapeutic Advances in Chronic Disease*, **2013**, 4, 192-205	4.9	22
89	Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. *Multiple Sclerosis Journal*, **2020**, 26, 1729-1739	5	22
88	Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. *Journal of the Neurological Sciences*, **2014**, 339, 196-206	3.2	21
87	Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. *Current Medical Research and Opinion*, **2009**, 25, 2459-70	2.5	21
86	Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. *Journal of Neurology*, **2014**, 261, 1781-8	5.5	20
85	Phenotypic and functional characteristics of activated CD8+ cells: a CD11b-CD28- subset mediates noncytolytic functional suppression. *Clinical Immunology and Immunopathology*, **1991**, 60, 254-67		20
84	A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. *Journal of Medical Internet Research*, **2020**, 22, e16932	7.6	20
83	Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. *Journal of Neurology*, **2017**, 264, 1068-1075	5.5	18
82	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. *Canadian Journal of Neurological Sciences*, **2020**, 47, 437-455	1	18
81	Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: a test utilization study. *American Journal of Clinical Pathology*, **2012**, 138, 262-72	1.9	18
80	gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression. *Clinical Immunology*, **2002**, 103, 309-16	9	18
79	Blood Neurofilament Light Chain: The Neurologist's Troponin?. *Biomedicines*, **2020**, 8,	4.8	18
78	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2017**, 3, 2055217317732802	2	17
77	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies. *Multiple Sclerosis and Related Disorders*, **2016**, 7, 33-40	4	17
76	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. *Multiple Sclerosis Journal*, **2014**, 20, 234-42	5	17
75	gamma delta T-cell-human glial cell interactions. II. Relationship between heat shock protein expression and susceptibility to cytolysis. *Journal of Neuroimmunology*, **1997**, 74, 143-8	3.5	17

74	Efficacy of subcutaneous interferon β1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 647-53	5.5	16
73	Bone marrow transplantation: does it stop MS progression?. *Journal of the Neurological Sciences*, **2007**, 259, 85-9	3.2	16
72	Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidence. *Neurological Sciences*, **2008**, 29 Suppl 2, S250-2	3.5	16
71	Immunoregulatory properties of T-cell lines derived from the systemic and intrathecal compartments: a phenotypic and functional study. *Annals of Neurology*, **1990**, 27, 258-65	9.4	16
70	Tests of information processing speed: what do people with multiple sclerosis think about them?. *International Journal of MS Care*, **2012**, 14, 92-9	2.3	16
69	A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2017**, 3, 2055217317730096	2	15
68	MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. *BMC Neurology*, **2009**, 9, 19	3.1	15
67	Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. *Multiple Sclerosis Journal*, **2020**, 26, 1083-1092	5	15
66	Cognition in early relapsing-remitting multiple sclerosis: consequences may be relative to working memory. *Journal of the International Neuropsychological Society*, **2013**, 19, 938-49	3.1	14
65	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. *Brain Imaging and Behavior*, **2019**, 13, 1361-1374	4.1	14
64	Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment. *Multiple Sclerosis Journal*, **2020**, 26, 540-547	5	13
63	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. *Annals of Clinical and Translational Neurology*, **2018**, 5, 346-356	5.3	13
62	Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 1019-27	4	13
61	Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. *Cold Spring Harbor Perspectives in Medicine*, **2019**, 9,	5.4	13
60	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. *Multiple Sclerosis and Related Disorders*, **2019**, 33, 131-138	4	12
59	Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis. *Neurotherapeutics*, **2017**, 14, 888-893	6.4	12
58	Patient subgroup analyses of the treatment effect of subcutaneous interferon β1a on development of multiple sclerosis in the randomized controlled REFLEX study. *Journal of Neurology* , **2014**, 261, 490-9	5.5	12
57	Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2019**, 5, 2055217319885983	2	12

56	Disability progression in aggressive multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 456-463	5	11
55	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. *Multiple Sclerosis Journal*, **2018**, 24, 535-539	5	11
54	Neurorepair with mesenchymal stem cells: hope or hype?. *Lancet Neurology, The*, **2012**, 11, 123-5	24.1	11
53	Herpes zoster ophthalmicus with delayed cerebral infarction and meningoencephalitis. *Canadian Journal of Neurological Sciences*, **1987**, 14, 312-4	1	11
52	Severe, Highly Active, or Aggressive Multiple Sclerosis. *CONTINUUM Lifelong Learning in Neurology*, **2016**, 22, 761-84	3	11
51	Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. *CNS Drugs*, **2021**, 35, 385-402	6.7	11
50	Serum neurofilament light in MS: The first true blood-based biomarker?. *Multiple Sclerosis Journal*, **2021**, 1352458521993066	5	11
49	Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. *Frontiers in Neuroscience*, **2021**, 15, 654942	5.1	11
48	The evaluation of MRI diffusion values of active demyelinating lesions in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2016**, 10, 97-102	4	10
47	Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence. *Neurology: Clinical Practice*, **2011**, 1, 66-68	1.7	10
46	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2020**, 7, 767-775	5.3	10
45	Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. *Neurology*, **2020**, 94, e1950-e1960	6.5	10
44	Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. *Therapeutic Advances in Neurological Disorders*, **2014**, 7, 279-88	6.6	9
43	Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. *Journal of the Neurological Sciences*, **2014**, 336, 132-7	3.2	9
42	Differential responses of CD4+CD45RA+ and CD4+CD29+ subsets to activated CD8+ cells: enhanced stimulation of the CD4+CD45RA+ subset by cells from patients with multiple sclerosis. *Cellular Immunology*, **1991**, 133, 306-16	4.4	9
41	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. *Lancet Neurology, The*, **2021**, 20, 917-929	24.1	9
40	Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 1764-1772	5	9
39	Imaging cognitive fatigability in multiple sclerosis: objective quantification of cerebral blood flow during a task of sustained attention using ASL perfusion fMRI. *Brain Imaging and Behavior*, **2020**, 14, 2417-2428	4.1	9

38	Early MRI results and odds of attaining Sno evidence of disease activitySstatus in MS patients treated with interferon 1a in the EVIDENCE study. *Journal of the Neurological Sciences*, **2017**, 379, 151-156	3.2	8
37	T cells and multiple sclerosis: Friends, foes, or both?. *Autoimmunity Reviews*, **2011**, 10, 364-7	13.6	7
36	Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. *Multiple Sclerosis and Related Disorders*, **2020**, 46, 102438	4	7
35	Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 1055-1066	5	6
34	Present and emerging therapies for multiple sclerosis. *CONTINUUM Lifelong Learning in Neurology*, **2013**, 19, 968-91	3	6
33	Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS care. *Canadian Journal of Neurological Sciences*, **2013**, 40, 527-35	1	6
32	Improving long-term follow-up studies of immunomodulatory therapies. *Neurology*, **2011**, 76, S35-8	6.5	6
31	Evaluating response to disease-modifying therapy in relapsing multiple sclerosis. *Expert Review of Neurotherapeutics*, **2015**, 15, 407-23	4.3	4
30	Efficacy and safety of subcutaneous interferon-1a in patients with a first demyelinating event and early multiple sclerosis. *Expert Opinion on Biological Therapy*, **2014**, 14, 1207-14	5.4	4
29	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. *Multiple Sclerosis Journal*, **2019**, 25, 565-573	5	4
28	Does Resetting the Immune System Fix Multiple Sclerosis?. *Canadian Journal of Neurological Sciences*, **2020**, 47, 1-10	1	4
27	The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis. *Journal of Neuro-Ophthalmology*, **2018**, 38, 210-216	2.6	4
26	A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2021**, 52, 102945	4	4
25	Study of Herpesvirus saimiri immortalization of gammadelta T cells derived from peripheral blood and CSF of multiple sclerosis patients. *Journal of Neuroimmunology*, **2003**, 139, 119-32	3.5	3
24	High or increasing serum NfL is predictive of impending multiple sclerosis relapses.. *Multiple Sclerosis and Related Disorders*, **2022**, 59, 103535	4	3
23	Research-to-Practice Gaps in Multiple Sclerosis Care for Patients with Subjective Cognitive, Mental Health, and Psychosocial Concerns in a Canadian Center. *International Journal of MS Care*, **2019**, 21, 243-248	2.3	3
22	Multiple sclerosis: Is there a safe time to discontinue therapy in MS?. *Nature Reviews Neurology*, **2016**, 13, 10-11	15	2
21	Disease-specific therapy of idiopathic inflammatory demyelinating disorders. *Expert Review of Neurotherapeutics*, **2012**, 12, 1113-24	4.3	2

20	The role of heat shock proteins in oligodendrocyte–T cell interaction. *Journal of Neuroimmunology*, **1991**, 35, 112	3.5	2
19	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2020**, 6, 2055217320972137	2	2
18	Tolerability and discontinuation rates in teriflunomide-treated patients. A real-world clinical experience. *Journal of King Abdulaziz University, Islamic Economics*, **2018**, 23, 204-207	1.1	2
17	Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. *Multiple Sclerosis Journal*, **2021**, 13524585211035740	5	2
16	Immunoablation and aHSCT for aggressive multiple sclerosis - AuthorsSreply. *Lancet, The*, **2017**, 389, 908	40	1
15	Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. *Multiple Sclerosis Journal*, **2021**, 27, 167-173	5	1
14	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. *Multiple Sclerosis Journal*, **2022**, 13524585211061861	5	1
13	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a. *Multiple Sclerosis and Related Disorders*, **2019**, 39, 101891	4	1
12	Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. *BMC Neurology*, **2020**, 20, 364	3.1	1
11	MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. *Multiple Sclerosis and Related Disorders*, **2021**, 49, 102790	4	1
10	Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. *Journal of Clinical Neuroscience*, **2019**, 59, 229-231	2.2	1
9	Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. *Journal of Neurology*, **2020**, 267, 64-75	5.5	1
8	Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2018**, 4, 2055217318775236	2	1
7	Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 2055217321990852	2	1
6	Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis. *Journal of the Neurological Sciences*, **2021**, 421, 117324	3.2	0
5	Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION. *Journal of Neuroimmunology*, **2021**, 360, 577715	3.5	0
4	Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial.. *Multiple Sclerosis and Related Disorders*, **2022**, 61, 103779	4	0
3	Managing relapsing–remitting multiple sclerosis following first drug failure. *Neurodegenerative Disease Management*, **2011**, 1, 115-126	2.8	

2	Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis.. *Clinical Neurophysiology*, **2022**, 136, 69-81	4.3
1	Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol.. *Current Protocols*, **2022**, 2, e437	